Cargando…
TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy
Tumor necrosis factor superfamily member 14 (LIGHT) has been in pre-clinical development for over a decade and shows promise as a modality of enhancing treatment approaches in the field of cancer immunotherapy. To date, LIGHT has been used to combat cancer in multiple tumor models where it can be co...
Autores principales: | Skeate, Joseph G., Otsmaa, Mikk E., Prins, Ruben, Fernandez, Daniel J., Da Silva, Diane M., Kast, W. Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243824/ https://www.ncbi.nlm.nih.gov/pubmed/32499782 http://dx.doi.org/10.3389/fimmu.2020.00922 |
Ejemplares similares
-
Comprehensive characterization of TNFSF14/LIGHT with implications in prognosis and immunotherapy of human gliomas
por: Han, Mingzhi, et al.
Publicado: (2022) -
Theta-Defensins Inhibit High-Risk Human Papillomavirus Infection Through Charge-Driven Capsid Clustering
por: Skeate, Joseph G., et al.
Publicado: (2020) -
TNFSF14 (LIGHT) Exhibits Inflammatory Activities in Lung Fibroblasts Complementary to IL-13 and TGF-β
por: da Silva Antunes, Ricardo, et al.
Publicado: (2018) -
Plasma TNFSF13B and TNFSF14 Function as Inflammatory Indicators of Severe Adenovirus Pneumonia in Pediatric Patients
por: Fan, Huifeng, et al.
Publicado: (2021) -
LIGHT/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic Regimens
por: Brunetti, Giacomina, et al.
Publicado: (2018)